The survival kinase Mirk/Dyrk1B is a downstream effector of oncogenic K-ras in pancreatic cancer

Cancer Research

Volumn 67, Issue 15, 2007, Pages 7247-7255

  Jin, Kideok ^a   Park, Sunju ^a   Ewton, Daina Z ^a   Friedman, Eileen ^a  

^a State University of New York Upstate Medical University: College of Medicine   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DYRK1B PROTEIN KINASE; MIRK PROTEIN KINASE; PROTEIN KINASE; PROTEIN SERINE THREONINE KINASE; RAC1 PROTEIN; UNCLASSIFIED DRUG;

ARTICLE; CANCER CELL CULTURE; CELL SURVIVAL; CLONOGENESIS; CONTROLLED STUDY; DIPLOIDY; ENZYME ACTIVATION; FIBROBLAST; GENE EXPRESSION; GENE MUTATION; HUMAN; HUMAN CELL; KNOCKOUT GENE; LETHALITY; ONCOGENE RAS; PANCREAS ADENOCARCINOMA; PANCREAS CANCER; PRIORITY JOURNAL; PROTEIN DEPLETION; RNA INTERFERENCE; RNA ISOLATION; TRANSIENT EXPRESSION;

ANIMALS; CARCINOMA, PANCREATIC DUCTAL; CELL ADHESION; CELL LINE; COLONY-FORMING UNITS ASSAY; DOGS; ENZYME ACTIVATION; FIBROBLASTS; GENES, RAS; HUMANS; IMMUNOPRECIPITATION; MICE; MICE, KNOCKOUT; MITOGEN-ACTIVATED PROTEIN KINASES; PANCREATIC NEOPLASMS; PROTEIN-SERINE-THREONINE KINASES; PROTEIN-TYROSINE KINASES; RAC1 GTP-BINDING PROTEIN; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION; TRANSFECTION;

EID: 34547630697     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-06-4099     Document Type: Article

References (36)

1. Karhu R, Mahlamaki E, Kallioniemi A. Pancreatic adenocarcinoma - genetic portrait from chromosomes to microarrays. Genes Chromosomes Cancer 2006;45:721-30.
2. Heidenblad M, Schoenmakers E, Jonson T, et al. Genome-wide array-based comparative genomic hybridization reveals multiple amplification targets and novel homozygous deletions in pancreatic carcinoma cell lines. Cancer Res 2004;64:3052-9.
3. Deng X, Ewton DZ, Li S, et al. The kinase Mirk/Dyrk1B mediates cell survival in pancreatic ductal adenocarcinoma. Cancer Res 2006;66:4149-58.
4. Jin K, Lim S, Mercer SE, Friedman E. The survival kinase Mirk/dyrk1B is activated through Rac1-3 signaling. J Biol Chem 2005;280:42097-105.
5. Lee K, Deng X, Friedman E. Mirk protein kinase is a mitogen-activated protein kinase substrate that mediates survival of colon cancer cells. Cancer Res 2000;60:3631-7.
6. Lim S, Jin K, Friedman E. Mirk protein kinase is activated by MKK3 and functions as a transcriptional activator of HNF1α. J Biol Chem 2002;277:25040-6.
7. Deng X, Ewton DZ, Mercer SE, Friedman E. Mirk/dyrk1B decreases the nuclear accumulation of class II histone deacetylases during skeletal muscle differentiation. J Biol Chem 2005;280:4894-905.
8. Bos J. Ras oncogenes in human cancer: a review. Cancer Res 1989;49:4682-9.
9. Hruban R, Iacobuzio-Donahue C, Wilentz R, Goggins M, Kern S. Molecular pathology of pancreatic cancer. Cancer J 2001;7:251-8.
10. Deng X, Ewton DZ, Pawlikowski B, Maimone M, Friedman E. Mirk/dyrk1B Is a Rho-induced kinase active in skeletal muscle differentiation. J Biol Chem 2003;278:41347-54.
11. Deng X, Mercer SE, Shah S, Ewton DZ, Friedman E. The cyclin-dependent kinase inhibitor p27Kip1 is stabilized in G0 by Mirk/dyrk1B kinase. J Biol Chem 2004;279:22498-504.
12. Leder S, Czajkowska H, Maenz B, et al. Alternative splicing variants of the protein kinase DYRK1B exhibit distinct patterns of expression and functional properties. Biochem J 2003;372:881-8.
13. Lambert JM, Lambert QT, Reuther GW, et al. Tiam1 mediates Ras activation of Rac by a PI(3)K-independent mechanism. Nat Cell Biol 2002;4:621-5.
14. Malliri A, Rygiel TP, van der Kammen RA, et al. The Rac activator Tiam1 is a Wnt-responsive gene that modifies intestinal tumor development. J Biol Chem 2006;281:543-8.
15. Baines AT, Lim K, Shields JM, et al. Use of retrovirus expression of interfering RNA to determine the contribution of activated K-Ras and Ras effector expression to human tumor cell growth. In: Methods in enzymology: Academic Press; 2006. p. 556.
16. Gao Y, Dickerson JB, Guo F, Zheng J, Zheng Y. Rational design and characterization of a Rac GTPase-specific small molecule inhibitor. Proc Natl Aacd Sci U S A 2004;101:7618-23.
17. Agbunag C, Bar-Sagi D. Oncogenic K-ras drives cell cycle progression and phenotypic conversion of primary pancreatic duct epithelial cells. Cancer Res 2004;64:5659-63.
18. Tournier C, Whitmarsh AJ, Cavanagh J, Barrett T, Davis RJ. Mitogen-activated protein kinase kinase MKK7 is an activator of the c-Jun NH2-terminal kinase. Proc Natl Acad Sci U S A 1997;94:7337-42.
19. Han J, Lee J, Jiang Y, Li Z, Feng L, Ulevitch R. Characterization of the structure and function of a novel MAP kinase kinase (MKK6). J Biol Chem 1996;271:2886-91.
20. Zheng C, Guan K. Cloning and characterization of two distinct human extracellular signal-regulated kinase activator kinases, MEK1 and MEK2. J Biol Chem 1993;268:11435-9.
21. Wu J, Harrison J, Dent P, Lynch K, Weber M, Sturgill T. Identification and characterization of a new mammalian mitogen-activated protein kinase kinase, MKK2. Mol Cell Biol 1993;13:4539-48.
22. Bardeesy N, DePinho R. Pancreatic cancer biology and genetics. Nat Rev Cancer 2002;2:897-909.
23. Berman D, Karhadkar S, Maitra A, et al. Widespread requirement for Hedgehog ligand stimulation in growth of digestive tract tumours. Nature 2003;425:846-50.
24. Thayer S, di Magliano M, Heiser P, et al. Hedgehog is an early and late mediator of pancreatic cancer tumorigenesis. Nature 2003;425:851-6.
25. Klimstra D, Longnecker DS. K-ras mutations in pancreatic ductal proliferative lesions. Am J Pathol 1994;145:1547-50.
26. Hingorani S, Petricoin E, Maitra A, et al. Preinvasive and invasive ductal pancreatic cancer and its early detection in the mouse. Cancer Cell 2003;4:437-50.
27. Aguirre AJ, Bardeesy N, Sinha M, et al. Activated Kras and Ink4a/Arf deficiency cooperate to produce metastatic pancreatic ductal adenocarcinoma. Genes Dev 2003;17:3112-26.
28. Lim K-H, Baines AT, Fiordalisi JJ, et al. Activation of RalA is critical for Ras-induced tumorigenesis of human cells. Cancer Cell 2005;7:533.
29. Jullien-Flores V, Dorseuil O, Romero F, et al. Bridging Ral GTPase to Rho pathways. J Biol Chem 1995;270:22473-7.
30. Crnogorac-Jurcevic T, Efthimiou E, Capelli P, et al. Gene expression profiles of pancreatic cancer and stromal desmoplasia. Oncogene 2001;20:4737-46.
31. Collins CS, Hong J, Sapinoso L, et al. A small interfering RNA screen for modulators of tumor cell motility identifies MAP4K4 as a promigratory kinase. Proc Natl Acad Sci U S A 2006;103:3775-80.
32. Khwaja A. Akt is more than just a Bad kinase. Nature 1999;401:33-4.
33. Datta S, Brunet A, Greenberg M. Cellular survival: a play in three Akts. Genes Dev 1999;13:2905-27.
34. Hennessy B, Smith DL, Ram P, Lu Y, Mills GB. Exploiting the PI3K/Akt pathway for cancer drug discovery. Nat Rev Drug Discov 2005;4:988-1004.
35. Asano T, Yao Y, Zhu J, Abbruzzese J, Reddy S. The PI 3-kinase/Akt signaling pathway is activated due to aberrant Pten expression and targets transcription factors NF-B and c-Myc in pancreatic cancer cells. Oncogene 2004;23:8571-80.
36. Locke M, Heywood M, Fawell S, Mackenzie IC. Retention of intrinsic stem cell hierarchies in carcinoma-derived cell lines. Cancer Res 2005;65:8944-50.